Rogers Corp. (ROG)

129.94
2.90 2.20
NYSE : Electronic Technology
Prev Close 132.81
Open 131.80
Day Low/High 128.94 / 133.08
52 Wk Low/High 105.60 / 184.00
Volume 18.02K
Avg Volume 127.60K
Exchange NYSE
Shares Outstanding 18.39M
Market Cap 2.33B
EPS 4.40
P/E Ratio 32.49
Div & Yield N.A. (N.A)

Latest News

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from...

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of studies across its industry-leading oncology portfolio of approved and investigational medicines will be presented at the European...

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median...

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in spinal muscular atrophy (SMA).

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee...

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower133 study of TECENTRIQ ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III IMpower132 study of TECENTRIQ ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial...

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which...

Noteworthy Thursday Option Activity: ROG, LXRX, MEET

Noteworthy Thursday Option Activity: ROG, LXRX, MEET

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Rogers Corp. , where a total of 728 contracts have traded so far, representing approximately 72,800 underlying shares.

Rogers Corporation Appoints Michael M. Ludwig Chief Financial Officer

Rogers Corporation Appoints Michael M. Ludwig Chief Financial Officer

Rogers Corporation (NYSE:ROG), a global leader in engineered material solutions, announced today that Michael M.

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be presented at the International Association for the Study of Lung...

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and...

Rogers Purchases Dielectric And Lamination Manufacturing Assets In Chandler, Ariz.

Rogers Purchases Dielectric And Lamination Manufacturing Assets In Chandler, Ariz.

Rogers Corporation (NYSE:ROG), a global leader in engineered material solutions, announced the purchase of certain dielectric and lamination manufacturing assets located in Chandler, Arizona from ISOLA USA Corp.

Roche Receives FDA Approval For Cobas EGFR Mutation Test V2 As Companion Diagnostic With IRESSA (gefitinib) In First-line Treatment Of Patients With Non-small Cell Lung Cancer (NSCLC)

Roche Receives FDA Approval For Cobas EGFR Mutation Test V2 As Companion Diagnostic With IRESSA (gefitinib) In First-line Treatment Of Patients With Non-small Cell Lung Cancer (NSCLC)

- New indication approval for cobas EGFR Mutation Test v2 as companion diagnostic, follows previous approvals with Tarceva (erlotinib) and TAGRISSO (osimertinib)

New Cervical Cancer Screening Guidelines Recommend HPV Testing Alone

New Cervical Cancer Screening Guidelines Recommend HPV Testing Alone

- US Preventive Services Task Force updated guidelines add primary HPV testing as recommended screening method for women 30-65

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Rogers Corporation Reports Second Quarter 2018 Results

Rogers Corporation Reports Second Quarter 2018 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2018 second quarter.

Roche To Showcase How Labs Are Driving Change Across Health Networks To Address PAMA And Other Challenges At AACC 2018 Clinical Lab Expo

Roche To Showcase How Labs Are Driving Change Across Health Networks To Address PAMA And Other Challenges At AACC 2018 Clinical Lab Expo

- Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care

Roche's Cobas HPV Test Receives FDA Approval For First-line Cervical Cancer Screening Using SurePath Preservative Fluid

Roche's Cobas HPV Test Receives FDA Approval For First-line Cervical Cancer Screening Using SurePath Preservative Fluid

- Roche test is now the only HPV test approved for first-line screening with two most common collection media for Pap tests

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people...

Biogen Jumps on Earnings Beat Ahead of Alzheimer's Presentation

Biogen Jumps on Earnings Beat Ahead of Alzheimer's Presentation

The biotech giant also raised its 2018 guidance for both revenue and earnings.

Rogers Schedules Q2 2018 Earnings Call For Jul 31

Rogers Schedules Q2 2018 Earnings Call For Jul 31

Rogers Corporation (NYSE:ROG) plans to announce second quarter 2018 results on July 31 after market close, which will be followed by a conference call at 5pm ET.

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present 16 new data presentations across its Alzheimer's disease (AD) pipeline at this year's Alzheimer's Association International Conference (AAIC) from...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab)...

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

TheStreet Quant Rating: B+ (Buy)